Medical/Pharmaceuticals
ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE
Article addresses role of advocacy in advancing healthy vision to meet Sustainable Development Goals DALLAS, Aug. 10, 2022 /PRNewswire/ -- OneSight EssilorLuxottica Foundation (Foundation) is pleased to announce the publication of a peer-reviewed article, The Power of Advocacy: Advancing Vision f...
2022-08-10 02:00
3334
Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth
Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ -- Frost & Sullivan Institute is proud to present Samsung Biologics wi...
2022-08-09 21:17
3350
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
* Reduces process development time by an estimated 40 percent * Enables biopharmaceutical companies to increase the speed to clinical manufacturing * Adds to company's best-in-class VirusExpress® Lentiviral Production Platform DARMSTADT,Germany, Aug. 9, 2022 /PRNewswire/ -- Merck, a leading s...
2022-08-09 20:00
4607
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and...
2022-08-09 19:00
3284
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first line treatment of advanced Non-Small Cell Lung Cancer (NS...
2022-08-09 11:18
4114
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively * Up to 72.4% of participants achieved weight loss of at least 5% at week 14 * XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly repor...
2022-08-09 08:00
3737
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
* FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activityin vitro and in vivo * Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent anti...
2022-08-09 00:00
4199
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreata...
2022-08-08 20:00
4676
Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device
- Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally. - The test utilises a CE-certified blood collection device, which is a proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process....
2022-08-08 16:45
4480
Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development
BEIJING, Aug. 8, 2022 /PRNewswire/ -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in eastChina's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than30 billion yu...
2022-08-08 12:24
4495
Qmed Asia launches Qmed GO "Mini Clinics" to Solve Rising Employee Healthcare Costs
Disrupting the medical landscape through an innovative internet-enabled
clinical kiosk.
KUALA LUMPUR, Malaysia, Aug. 8, 2022 /PRNewswire/ -- Qmed Asia
2022-08-08 10:15
3740
BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region's biggest bioindustry-focused conference and exhibition
Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang,Taipei, from 27-31 July, came to a successful conclusio...
2022-08-08 10:00
6117
BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs
SHANGHAI, Aug. 8, 2022 /PRNewswire/ -- BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (...
2022-08-08 09:06
4478
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Ma...
2022-08-08 08:10
3883
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator ProfessorYi-Long Wu was invited to highlight key data in a press conference * In the final progression-free survival analysis, sugemalimab showed sustained ...
2022-08-08 08:08
3756
Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer
SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the appointment of Dr. ...
2022-08-08 08:00
3713
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2022-08-08 08:00
4093
Telix and University of Queensland-led Consortium Awarded $5M Australian Research Council (ARC) Grant
MELBOURNE, Australia, Aug. 8, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has been jointly awarded a$4.8 million Australian Research Council (ARC) grant to establish a new Industrial Transformation Research Program (ITRP) Hub as part o...
2022-08-08 07:55
3694
BGI's Global Life Science Research Leadership Recognized in 2022 Nature Index
SHENZHEN, China, Aug. 5, 2022 /PRNewswire/ -- BGI's leading global position in life science research has been recognized in the 2022 Nature Index. BGI rose two places to 8th in the world among corporate institutions for its contribution to life science research and was the only Chinese corporate ...
2022-08-05 22:18
5927
Innovent Biologics and Sanofi Enter Strategic Collaboration to Accelerate Development of Oncology Medicines and Expand Presence in China
* Collaboration to accelerate the development and access of oncology medicines for cancer patients inChina * Clinical trial programs combining two of Sanofi's prioritized oncology assets with sintilimab, the leading checkpoint inhibitor inChina, to address some of the most prevalent solid tum...
2022-08-04 23:30
5759
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 309 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 281 media titles]
2026-10-23 21:52
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 276 media titles]
2026-10-28 09:00
Most Read
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
41103
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
40932
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
40019
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
32251